checkAd
Oxurion Aktie
1,833
 
EUR
20:39:03 Lang & Schwarz
+1,78 %
+0,032 EUR
Geldkurs 20:39:03
1,782 EUR
2.777 Stk.
Briefkurs 20:39:03
1,884 EUR
2.777 Stk.

Leuven, BE, Boston, MA, US – April 13th, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a clinical stage portfolio in retinal vascular …

Wertpapier:

Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data from a Phase 1 dose escalation study of TB-403 …

Wertpapier:

Nachrichten

DatumTitel
09.04.21ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting
globenewswire | Weitere Nachrichten
07.04.21Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
globenewswire | Weitere Nachrichten
06.04.21Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
globenewswire | Weitere Nachrichten
31.03.21OXURION to Participate in Upcoming Investor Meetings
globenewswire | Weitere Nachrichten
17.03.21Oxurion NV Business and Financial Update – FY 2020
globenewswire | Weitere Nachrichten
08.03.21OXURION to Participate in Upcoming Investor Meetings
globenewswire | Weitere Nachrichten
20.01.21Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
globenewswire | Weitere Nachrichten
07.01.21OXURION to Participate in Upcoming Investor Meetings
globenewswire | Weitere Nachrichten
09.11.20OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
globenewswire | Weitere Nachrichten
22.10.20ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program
globenewswire | Weitere Nachrichten
15.10.20Oxurion NV Business Update – Q3 2020
globenewswire | Weitere Nachrichten
13.10.20Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
globenewswire | Weitere Nachrichten
08.10.20Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET
globenewswire | Weitere Nachrichten
05.10.20Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020
globenewswire | Weitere Nachrichten
29.09.20Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4
globenewswire | Weitere Nachrichten